We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Grifols (GRFS) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Grifols (GRFS - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Grifols is one of 954 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Grifols is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for GRFS' full-year earnings has moved 1% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, GRFS has gained about 26.2% so far this year. At the same time, Medical stocks have gained an average of 4%. This shows that Grifols is outperforming its peers so far this year.
Arcutis Biotherapeutics, Inc. (ARQT - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 81.6%.
In Arcutis Biotherapeutics, Inc.'s case, the consensus EPS estimate for the current year increased 19.9% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Breaking things down more, Grifols is a member of the Medical - Drugs industry, which includes 145 individual companies and currently sits at #90 in the Zacks Industry Rank. This group has gained an average of 7.3% so far this year, so GRFS is performing better in this area.
On the other hand, Arcutis Biotherapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry. This 470-stock industry is currently ranked #93. The industry has moved +10.5% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Grifols and Arcutis Biotherapeutics, Inc. as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Grifols (GRFS) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Grifols (GRFS - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Grifols is one of 954 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Grifols is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for GRFS' full-year earnings has moved 1% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, GRFS has gained about 26.2% so far this year. At the same time, Medical stocks have gained an average of 4%. This shows that Grifols is outperforming its peers so far this year.
Arcutis Biotherapeutics, Inc. (ARQT - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 81.6%.
In Arcutis Biotherapeutics, Inc.'s case, the consensus EPS estimate for the current year increased 19.9% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Breaking things down more, Grifols is a member of the Medical - Drugs industry, which includes 145 individual companies and currently sits at #90 in the Zacks Industry Rank. This group has gained an average of 7.3% so far this year, so GRFS is performing better in this area.
On the other hand, Arcutis Biotherapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry. This 470-stock industry is currently ranked #93. The industry has moved +10.5% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Grifols and Arcutis Biotherapeutics, Inc. as they could maintain their solid performance.